Fingerprint technology provides a quantitative analysis of the glycans in a protein sample without protein purification or cleavage
Procognia and Xcellerex announced an agreement to provide Procognia's rapid glycoanalysis to Xcellerex customers. Xcellerex applies advanced biomanufacturing technologies in the biologics contract manufacturing industry.
Procognia has developed technology that enables the rapid assessment of product structure and comparability using rapid analysis of the glycosylation of intact glycoprotein samples directly in culture medium.
Procognia's U-c fingerprint technology provides a quantitative analysis of the glycans in a protein sample without protein purification or cleavage.
Up to 40 protein samples can be analysed in under six hours with minimal 'hands-on' time.
As current tools for analysing glycosylation are not amenable to real-time analysis and monitoring, the speed and ease of use of Procognia's technology enables rapid development of biotherapeutics.
Xcellerex is dedicated to speeding medicines to people and offers contract high speed and high output process development and manufacturing technologies for biotherapeutics, vaccines and personalised medicines.
Integration of Procognia U-c fingerprint technology into Xcellerex's services will permit Xcellerex to rapidly identify and retain the desired glycosylation patterns of products as they undergo process optimization, scale up for manufacturing and clinical development.
Parrish Galliher, president and CEO of Xcellerex, commented "I am very pleased to offer this critical service to our clients.
"Procognia's technology will further improve the speed and success with which we can advance our clients' products to the clinic and the market".
Ron Long, CEO of Procognia indicated "We feel that our relationship with an innovative biologics process development and manufacturing organisation such as Xcellerex is an important step in improving the quality of biologic products available to patients."
